THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSEDPurchase Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
The Delivery Price for the Contracted Doses and any Additional Order is to be paid by the Participating Member State to the Participating Contractor Affiliate [***]. [***]
FIRST AMENDMENT TO THE COLLABORATION AGREEMENTCollaboration Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO THE COLLABORATION AGREEMENT ("First Amendment") is made and entered into, effective as of June 1, 2018 ("Amendment Effective Date"), by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany ("RNP") and BioNTech AG, a stock corporation organized under the laws of Germany ("BNT") (RNP and BNT collectively, "BioNTech"), and Genentech, Inc., a corporation organized under the laws of the State of Delaware ("GNE") and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland ("Roche") (GNE and Roche, collectively, "Genentech"). BioNTech and Genentech are sometimes referred to herein individually as a "Party" and collectively as the "Parties ."
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SECOND AMENDMENT TO THE...Collaboration Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
This SECOND AMENDMENT (the “Second Amendment”) is made and entered into, effective as of December 6, 2019 (the “Second Amendment Effective Date”), by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (“RNP”) and BioNTech SE, a European stock corporation (“BNT”) (RNP and BNT collectively, “BioNTech”), and Genentech, Inc., a corporation organized under the laws of the State of Delaware (“GNE”) and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”).
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, ANDPatent Sublicense Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
This is the Second Amendment ("Second Amendment") to the Patent Sublicense Agreement which became effective on July 19, 2017, as amended in the First Amendment which became effective on February 10, 2020 (together, the “Agreement”) by and between mRNA RiboTherapeutics, Inc., a Wisconsin company (“mRNA RiboTherapeutics”) and BioNTech RNA Pharmaceuticals GmbH, a German corporation (“Company”). This Second Amendment is effective as of August 1, 2020 ("Second Amendment Effective Date"). mRNA RiboTherapeutics and Company may herein each be referred to as a "Party" or collectively as the "Parties".
JOINDER AND THIRD AMENDMENT TO THE COLLABORATION AGREEMENTCollaboration Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
This JOINDER AND THIRD AMENDMENT (the “Third Amendment”) is made and entered into, effective as of October 1, 2020 (the “Third Amendment Effective Date”), by and between (1) BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (“RNP”) and BioNTech SE, a European stock corporation (“BNT”) (RNP and BNT collectively, “BioNTech”), (2) Genentech, Inc., a corporation organized under the laws of the State of Delaware (“GNE”) and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”) and (3) BioNTech Manufacturing GmbH, a German limited liability company having its principal place of business at An der Goldgrube 12, 55131, Germany (“BMG”),
Amended and Restated collaboration AGREEMENTCollaboration Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances) • England and Wales
This Amended and Restated Collaboration Agreement (the “Agreement”) is entered into with effect as of March 17, 2020 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, New York, 10017 United States (“Pfizer”) and BioNTech SE, a corporation organized and existing under the laws of Germany and having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany (“BioNTech”). Pfizer and BioNTech are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ANNEX to the COMMISSION DECISION of 11.11.2020 approving an Advance Purchase Agreement on COVID-19 vaccinesAdvance Purchase Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, ANDPatent Sublicense Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
This is the Second Amendment ("Second Amendment") to the Patent Sublicense Agreement which became effective on July 19, 2017, as amended in the First Amendment which became effective on February 10, 2020 (together, the “Agreement”) by and between CELLSCRIPT, LLC, a Wisconsin company (“Cellscript”) and BioNTech RNA Pharmaceuticals GmbH, a German corporation (“Company”). This Second Amendment is effective as of August 1, 2020 ("Second Amendment Effective Date"). Cellscript and Company may herein each be referred to as a "Party" or collectively as the "Parties".
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, ANDCollaboration Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
This FOURTH AMENDMENT (the “Fourth Amendment”) is made and entered into, effective as of October 26, 2020 (the “Fourth Amendment Effective Date”), by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (“RNP”), BioNTech Manufacturing GmbH, a limited liability company organized under the laws of Germany (“BMG”) and BioNTech SE, a European stock corporation (“BNT”) (RNP, BMG and BNT collectively, “BioNTech”), and Genentech, Inc., a corporation organized under the laws of the State of Delaware (“GNE”) and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”).
